Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 112

Sort by

Sort Order Select

Journal Articles

Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial

Blood (2019) 134 (Supplement_1): 33.

https://doi.org/10.1182/blood-2019-126824

Published: 2019

Journal Articles

Developmental DNA Methylation Subtype Predicts Progression to Treatment and Survival in High-Count Monoclonal B Lymphocytosis

Brian Giacopelli, BS, Kari G. Chaffee, MS, Yue-zhong Wu, MSc, John C. Byrd, MD, Tait D. Shanafelt, MD, Sameer A. Parikh, MD, Esteban Braggio, PhD, Susan L. Slager, PhD, Neil E. Kay, MD, Christopher C. Oakes, PhD

Blood (2019) 134 (Supplement_1): 3022.

https://doi.org/10.1182/blood-2019-123564

Published: 2019

Journal Articles

Ibrutinib-Based Therapy Improves Anti-Tumor T Cell Killing Function Allowing Effective Pairing with Anti-PD-L1 Immunotherapy Compared to Traditional FCR Chemoimmunotherapy; Implications for Therapy and Correlative Immune Functional Data from the Phase III E1912 Trial

Despoina Papazoglou, BSc, Connie E. Lesnick, Victoria Wang, Neil E. Kay, MD, Tait D. Shanafelt, MD, Alan G. Ramsay, BSc,MSc,PhD

Blood (2018) 132 (Supplement 1): 236.

https://doi.org/10.1182/blood-2018-99-118333

Published: 2018

Journal Articles

Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy

Blood (2018) 132 (Supplement 1): 4394.

https://doi.org/10.1182/blood-2018-99-112989

Published: 2018

Journal Articles

A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)

Tait D. Shanafelt, MD, Victoria Wang, Neil E. Kay, MD, Curtis A. Hanson, MD, Susan M. O'Brien, MD, Jacqueline C Barrientos, MD, Harry P. Erba, MDPhD, Richard M. Stone, MD, Mark R. Litzow, MD, Martin S. Tallman, MD

Blood (2018) 132 (Supplement 1): LBA-4.

https://doi.org/10.1182/blood-2018-120779

Published: 2018

Journal Articles

Association between the Risk of Low/High-Count Monoclonal B-Cell Lymphocytosis (MBL) and the Chronic Lymphocytic Leukemia (CLL) Polygenic Risk Score (PRS)

Geffen Kleinstern, PhD, Sara J. Achenbach, Dennis P. Robinson, Aaron D. Norman, Kari G. Chaffee, MS, Connie E. Lesnick, Sameer A. Parikh, MD, Timothy G. Call, MD, Janet E. Olson, PhD, James R. Cerhan, MD PhD, Neil E. Kay, MD, Curtis A. Hanson, MD, Tait D. Shanafelt, MD, Susan L. Slager, PhD

Blood (2018) 132 (Supplement 1): 5538.

https://doi.org/10.1182/blood-2018-99-116414

Published: 2018

Journal Articles

The Magnitude of Improvement in Progression-Free Survival with Targeted Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia Based on Genetic Risk: A Systematic Review and Meta-Analysis

Stefano Molica, MD, Diana Giannarelli, PhD, Rosana Mirabelli, MD, Luciano Levato, Tait D. Shanafelt, MD

Blood (2018) 132 (Supplement 1): 5568.

https://doi.org/10.1182/blood-2018-99-112580

Published: 2018

Journal Articles

Telomere Length Is Associated with Epigenetic Programming in CLL and Is a Superior Predictor of Clinical Outcome with the Ability to Bifurcate Patients with the Same CLL-IPI Score

Kevin Norris, PhD, Christopher C. Oakes, Brian Giacopelli, BS, Tait D. Shanafelt, MD, Neil E. Kay, MD, Kari G. Chaffee, MS, Christopher Fegan, MD, Duncan M Baird, PhD, Chris Pepper, BSc, PhD

Blood (2018) 132 (Supplement 1): 1833.

https://doi.org/10.1182/blood-2018-99-114488

Published: 2018

Journal Articles

Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Chronic Lymphocytic Leukemia (CLL) Driver Genes: Risk of CLL and Monoclonal B-Cell Lymphocytosis (MBL)

Nicholas J Boddicker, PhD, Daniel R O'Brien, Esteban Braggio, PhD, Sara J. Achenbach, Kari G. Chaffee, MS, Aaron D. Norman, Celine M. Vachon, PhD, Brian Kabat, B.S., Timothy G. Call, MD, Sameer A. Parikh, MD, Jose F. Leis, MD PhD, Wei Ding, MD PhD, Eli Muchtar, MD, James R. Cerhan, MD PhD, Tait D. Shanafelt, MD, Neil E. Kay, MD, Neil E Caporaso, Susan L. Slager, PhD

Blood (2018) 132 (Supplement 1): 3116.

https://doi.org/10.1182/blood-2018-99-117044

Published: 2018

Journal Articles

PD-1 Expression in Chronic Lymphocytic Leukemia and Large B-Cell Richter Transformation (DLBCL-RT): A Distinguishing Feature for DLBCL-RT and Promising Surrogate Marker for Clonal Relatedness

Rong He, MD, Wei Ding, MD PhD, David Viswanatha, MD, Dong Chen, MD PhD, Min Shi, MD PhD, Daniel L. Van Dyke, PhD, Linda N Dao, MD, Sameer A. Parikh, MD, Tait D Shanafelt, MD, Timothy G. Call, MD, Stephen M Ansell, MD PhD, Jose F. Leis, MD PhD, Ming Mai, MS, Curtis A. Hanson, MD, Karen L Rech, MD

Blood (2017) 130 (Supplement 1): 4286.

https://doi.org/10.1182/blood.V130.Suppl_1.4286.4286

Published: 2017

Journal Articles

Targeted Deep Sequencing in Untreated Progressive CLL Helps to Better Dissect the Genomic Landscape and Shows Novel Associations between Mutations, Prognostic and Clinical Parameters: Data from E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group

Esteban Braggio, PhD, Victoria Wang, Laura Ann Bruins, BS, Santiago Barrio, PhD, Connie Lesnick, Jacqueline C. Barrientos, MD, Susan M. O'Brien, MD, Martin S. Tallman, MD, Mark R. Litzow, MD, Rafael Fonseca, MD, Neil E. Kay, MD, Tait D Shanafelt, MD

Blood (2017) 130 (Supplement 1): 4288.

https://doi.org/10.1182/blood.V130.Suppl_1.4288.4288

Published: 2017

Journal Articles

Invasive Aspergillosis in Chronic Lymphocytic Leukemia: Therapy and Outcomes

Narjust Duma, MD, Jonas Paludo, MD, Brian Kabat, B.S., Aaron Tande, MD, Kari G Chaffee, MS, Timothy G. Call, MD, Saad Sirop Kenderian, MD, Wei Ding, MD PhD, Jose F. Leis, MD PhD, Melissa C. Larson, M.S., Asher A. Chanan-Khan, MD, Michael Conte, PA-C, Susan Marie Schwager, Susan L Slager, PhD, Neil E. Kay, MD, Tait D. Shanafelt, MD, Sameer A. Parikh, MD

Blood (2017) 130 (Supplement 1): 4327.

https://doi.org/10.1182/blood.V130.Suppl_1.4327.4327

Published: 2017

Journal Articles

Prevalence of Low Count (LC) Monoclonal B Cell Lymphocytosis (MBL) and Serious Infections in a Population-Based Cohort of U.S. Adults Participating in a Large Bio-Repository

Tait D. Shanafelt, MD, Neil E. Kay, MD, Curtis A. Hanson, MD, Sameer A. Parikh, MD, Sara J Achenbach, Aaron Norman, Kari G Chaffee, MS, Susan Marie Schwager, Timothy G. Call, MD, Susan L Slager, PhD

Blood (2017) 130 (Supplement 1): 831.

https://doi.org/10.1182/blood.V130.Suppl_1.831.831

Published: 2017

Journal Articles

Changes in Quality of Life in Indolent Non-Hodgkin Lymphoma 3 Years after Diagnosis

Carrie A Thompson, MD, Kathleen Yost, PhD, Melissa C. Larson, M.S., Cristine Allmer, BS, Matthew J Maurer, MS, Amylou C. Dueck, PhD, Tait D. Shanafelt, MD, Thomas M Habermann, MD, Allison C. Rosenthal, DO, Umar Farooq, MD, Brian K Link, MD, James R Cerhan, MD PhD

Blood (2017) 130 (Supplement 1): 917.

https://doi.org/10.1182/blood.V130.Suppl_1.917.917

Published: 2017

Journal Articles

Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib in Routine Clinical Practice at an Academic Medical Center

Paul J. Hampel, MD, Melissa C. Larson, M.S., Brian Kabat, B.S., Timothy G. Call, MD, Wei Ding, MD PhD, Saad Sirop Kenderian, MD, Michael Conte, PA-C, Susan Marie Schwager, Jose F. Leis, MD PhD, Asher A. Chanan-Khan, MD, Susan L Slager, PhD, Neil E. Kay, MD, Kari G Chaffee, MS, Tait D. Shanafelt, MD, Sameer A. Parikh, MD

Blood (2017) 130 (Supplement 1): 3023.

https://doi.org/10.1182/blood.V130.Suppl_1.3023.3023

Published: 2017

Journal Articles

Factors Associated with Non-Melanoma Skin Cancer (NMSC) Among Chronic Lymphocytic Leukemia (CLL) Patients

Geffen Kleinstern, PhD, Abdul Rishi, Sara J Achenbach, Kari G Chaffee, MS, Neil E. Kay, MD, Tait D Shanafelt, MD, Jacob Inda, Aaron Norman, Timothy G. Call, MD, Christian L Baum, MD, James R. Cerhan, MD PhD, Susan L Slager, PhD

Blood (2017) 130 (Supplement 1): 2158.

https://doi.org/10.1182/blood.V130.Suppl_1.2158.2158

Published: 2017

Journal Articles

Chronic Lymphocytic Leukemia International Prognostic INDEX (CLL-IPI) Predicts Prognosis of CLL: A Systematic Review and Meta-Analysis

Stefano Molica, MD, Diana Giannarelli, PhD, Luciano Levato, MD, Rosana Mirabelli, MD, Tait D. Shanafelt, MD

Blood (2017) 130 (Supplement 1): 1739.

https://doi.org/10.1182/blood.V130.Suppl_1.1739.1739

Published: 2017

Journal Articles

Incidence of and Risk Factors for Major Hemorrhage in Patients Treated with Ibrutinib: Results from an Integrated Analysis

Blood (2017) 130 (Supplement 1): 1743.

https://doi.org/10.1182/blood.V130.Suppl_1.1743.1743

Published: 2017

Journal Articles

Common Genetic Polymorphisms Contribute to the Association between Non-Melanoma Skin Cancer and Chronic Lymphocytic Leukemia

Caroline Besson, MDPhD, Amy Moore, Wenting Wu, Nicola J Camp, PhD, Claire Vajdic, Lindsay M. Morton, PhD, Karin E Smedby, MD PhD, Silvia de Sanjose, Tait D Shanafelt, MD, Jerry Brewer, Lydia Zablotska, Eric A. Engels, MD MPH, James R. Cerhan, MD PhD, Susan L Slager, PhD, Jiali Han, Sonja I Berndt, PhD

Blood (2017) 130 (Supplement 1): 1454.

https://doi.org/10.1182/blood.V130.Suppl_1.1454.1454

Published: 2017

Journal Articles

Clinically Ascertained Monoclonal B-Cell Lymphocytosis: Risk of Progression to Chronic Lymphocytic Leukemia Requiring Therapy and Outcomes

Sameer A. Parikh, MD, Kari G Chaffee, MS, Timothy G. Call, MD, Jose F. Leis, MD, PhD, Wei Ding, MD PhD, Saad S Kenderian, MD, Asher A. Chanan-Khan, MD, Deborah A. Bowen, APRN, CNP, Michael J Conte, PA-C, Susan M. Schwager, Susan L. Slager, PhD, Curtis A. Hanson, MD, Neil E. Kay, MD, Tait D. Shanafelt, MD

Blood (2016) 128 (22): 3228.

https://doi.org/10.1182/blood.V128.22.3228.3228

Published: 2016

NARROW

Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial

Developmental DNA Methylation Subtype Predicts Progression to Treatment and Survival in High-Count Monoclonal B Lymphocytosis

Ibrutinib-Based Therapy Improves Anti-Tumor T Cell Killing Function Allowing Effective Pairing with Anti-PD-L1 Immunotherapy Compared to Traditional FCR Chemoimmunotherapy; Implications for Therapy and Correlative Immune Functional Data from the Phase III E1912 Trial

Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy

A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)

Association between the Risk of Low/High-Count Monoclonal B-Cell Lymphocytosis (MBL) and the Chronic Lymphocytic Leukemia (CLL) Polygenic Risk Score (PRS)

The Magnitude of Improvement in Progression-Free Survival with Targeted Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia Based on Genetic Risk: A Systematic Review and Meta-Analysis

Telomere Length Is Associated with Epigenetic Programming in CLL and Is a Superior Predictor of Clinical Outcome with the Ability to Bifurcate Patients with the Same CLL-IPI Score

Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Chronic Lymphocytic Leukemia (CLL) Driver Genes: Risk of CLL and Monoclonal B-Cell Lymphocytosis (MBL)

PD-1 Expression in Chronic Lymphocytic Leukemia and Large B-Cell Richter Transformation (DLBCL-RT): A Distinguishing Feature for DLBCL-RT and Promising Surrogate Marker for Clonal Relatedness

Targeted Deep Sequencing in Untreated Progressive CLL Helps to Better Dissect the Genomic Landscape and Shows Novel Associations between Mutations, Prognostic and Clinical Parameters: Data from E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group

Invasive Aspergillosis in Chronic Lymphocytic Leukemia: Therapy and Outcomes

Prevalence of Low Count (LC) Monoclonal B Cell Lymphocytosis (MBL) and Serious Infections in a Population-Based Cohort of U.S. Adults Participating in a Large Bio-Repository

Changes in Quality of Life in Indolent Non-Hodgkin Lymphoma 3 Years after Diagnosis

Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib in Routine Clinical Practice at an Academic Medical Center

Factors Associated with Non-Melanoma Skin Cancer (NMSC) Among Chronic Lymphocytic Leukemia (CLL) Patients

Chronic Lymphocytic Leukemia International Prognostic INDEX (CLL-IPI) Predicts Prognosis of CLL: A Systematic Review and Meta-Analysis

Incidence of and Risk Factors for Major Hemorrhage in Patients Treated with Ibrutinib: Results from an Integrated Analysis

Common Genetic Polymorphisms Contribute to the Association between Non-Melanoma Skin Cancer and Chronic Lymphocytic Leukemia

Clinically Ascertained Monoclonal B-Cell Lymphocytosis: Risk of Progression to Chronic Lymphocytic Leukemia Requiring Therapy and Outcomes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only